BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 33290193)

  • 1. Targeting the JAK/STAT Signaling Pathway for Breast Cancer.
    Shao F; Pang X; Baeg GH
    Curr Med Chem; 2021; 28(25):5137-5151. PubMed ID: 33290193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
    Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
    Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
    Yang X; Tang Z; Zhang P; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of JAK-STAT Signaling in Breast Cancer: Therapeutic Strategies to Overcome Drug Resistance.
    Tabassum S; Abbasi R; Ahmad N; Farooqi AA
    Adv Exp Med Biol; 2019; 1152():271-281. PubMed ID: 31456189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
    Bose S; Banerjee S; Mondal A; Chakraborty U; Pumarol J; Croley CR; Bishayee A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32545187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering JAK/STAT signaling pathway: A multifaceted approach to tumorigenesis, progression and therapeutic interventions.
    Wang Y; Wang Z; Li S; Ma J; Dai X; Lu J
    Int Immunopharmacol; 2024 Apr; 131():111846. PubMed ID: 38520787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
    Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
    Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
    Kwon S
    Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule drug discovery targeting the JAK-STAT pathway.
    Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
    Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.
    Zalpoor H; Nabi-Afjadi M; Forghaniesfidvajani R; Tavakol C; Farahighasreaboonasr F; Pakizeh F; Dana VG; Seif F
    Cell Mol Biol Lett; 2022 Jul; 27(1):60. PubMed ID: 35883021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK-STAT signaling as an ARDS therapeutic target: Status and future trends.
    Zhang Y; Gao Z; Jiang F; Yan H; Yang B; He Q; Luo P; Xu Z; Yang X
    Biochem Pharmacol; 2023 Feb; 208():115382. PubMed ID: 36528067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the NF-κB pathway enhances responsiveness of mammary tumors to JAK inhibitors.
    Bapat AS; O'Connor CH; Schwertfeger KL
    Sci Rep; 2023 Apr; 13(1):5349. PubMed ID: 37005447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance.
    Raychaudhuri SP; Shah RJ; Banerjee S; Raychaudhuri SK
    Curr Rheumatol Rep; 2024 Jun; 26(6):204-213. PubMed ID: 38492148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.
    Durham GA; Williams JJL; Nasim MT; Palmer TM
    Trends Pharmacol Sci; 2019 May; 40(5):298-308. PubMed ID: 30948191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
    Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
    Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors.
    Dinakar YH; Kumar H; Mudavath SL; Jain R; Ajmeer R; Jain V
    Life Sci; 2022 Nov; 309():120996. PubMed ID: 36170890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
    Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
    Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
    Tzeng HT; Chyuan IT; Lai JH
    Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.